Author(s):
Madhuri T. Deshmukh, Shrinivas K. Mohite
Email(s):
madhurideshmukh9@yahoo.com
DOI:
10.52711/0974-360X.2021.00339 
Address:
Madhuri T. Deshmukh1*, Shrinivas K. Mohite2
1Department of Pharmaceutics, Rajarambapu College of Pharmacy, Kasegaon 415404, Maharshtra, India.
2Department of Pharmaceutical Chemistry, Rajarambapu College of Pharmacy, Kasegaon 415404, Maharshtra.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2021
ABSTRACT:
Olanzepine a potential antidepressant drug with high affinity of serotonin (5-hydroxytryptamine, 5-HT), dopamine (DA) and noradrenaline (NA) in selected regions of the rat brain. Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Hence the purpose of present study is to investigate effect of Olanzepine microsphere prepared by using combination of sodium alginate and carbopol polymer on monoamine concentration in rat brain. Our main aim is to study relationship such as serotonin (5HT), dopamine (DA) and nonadrenaline (NA)in the brain of rat It showed that significant reduction occur in monoamine formation in brain of rat. Thus study suggest that prepared Olanzepine microsphere showed decreased the monoamine on rat brain.
Cite this article:
Madhuri T. Deshmukh, Shrinivas K. Mohite. Estimation of Monoamines concentration in rat brain after administration of Olanzepine Microsphere. Research Journal of Pharmacy and Technology. 2021; 14(4):1919-2. doi: 10.52711/0974-360X.2021.00339
Cite(Electronic):
Madhuri T. Deshmukh, Shrinivas K. Mohite. Estimation of Monoamines concentration in rat brain after administration of Olanzepine Microsphere. Research Journal of Pharmacy and Technology. 2021; 14(4):1919-2. doi: 10.52711/0974-360X.2021.00339 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-4-15
REFERENCES:
1. Porsolt DR., Pichon LM M., Jalpre M.; Depression: a model sensitive to antidepressant treatments; Nature; 1997; 266: 730-734.
2. Moussavi S, Chatterji S, Verdes E, et al: Depression, chronic Diseases, and Decrements in health: Results from the World Health Surveys Lancet 2007; 370: 851-858.
3. Nestler EJ, Barrot M, Di Leone RJ, et al: Neurobiology of Depression Neuron 2002; 34: 13–25.
4. Robert E., Hales RE.; Textbook of Psychiatry; 2008; (5): 154-156.
5. Hiemke C., Härtter S.; Pharmacokinetics of selective serotonin reuptake inhibitors; Pharmacology and Therapeutics; 2000; (85): 11–28.
6. Venkates Kumar K , Arunkumar N, Verma P, Prasad P, Neema G, Punitha K. Characterization of Olanzapine-solid Dispersions. International Journal of Pharma Research and Development2010; 10 (1): 13-24.
7. Patel C, Sahoo U, Seth A, Shah V, Upadhyay Formulation and evaluation of solid dispersion of Olanzepine. International Journal of Pharmacy and Pharmaceutical Science.; 2011; 1598-1605.
8. Amir B, Fazal S, Khalid R. Controlled Release Matrix Tablets of Olanzapine: Influence of Polymers on the In Vitro Release and Bioavailability. AAPS Pharm Sci Tech. 2010; 11(3): 1397-1404.
9. Sahu S., Chourasia A., Toppo A., Asati A.; Formulation and evaluation of Captropril microspheres by ionic Gelation Technique; International Journal of Pharmacy and Life Science. 2012; 3(1): 1377-1379.
10. Schlumfjf M., Liechtensteiner W., Langemann H., Peter G. Waser and Hefti F.; A Fluorometric Micro method for the simultaneous determination of Serotonin, Noradrenaline and Dopamine in milligram amounts of brain tissue; Pergamon Press, Printed M Great Britain. Biochemistry; Pharmacology; 1974; 23: 2337-2446.
11. Ali R., Banoth B., Gugulothu V., Dudhipala N., Sandhya R.; Estimation of biogenic amines concentrations in rat brain after administration of ageratum conyzoides extracts; International Journal of Medicinal Chemistry and Analysis; 1(1): 1-6.